TST003 / Transcenta - LARVOL DELTA

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov) - P1/2 | N=111 | Active, not recruiting | Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. | Recruiting ➔ Active, not recruiting | N=76 ➔ 111

Enrollment change • Enrollment closed • Metastases • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors (AACR 2024) - P1/2 | "The enrollment is ongoing in clinical centers in the US and China. No significant safety signals were reported in the first few patients treated with TST003.Clinical Trial Information: NCT05731271.Study Sponsor: Suzhou Transcenta Therapeutics Co., Ltd."

Clinical • Metastases • P1 data • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BMP2 • GREM1 • TGFB1

The preclinical characterization of TST003, a first-in-class mAb targeting gremlin-1 overexpressed by cancer-associated fibroblasts and tumor cells (AACR 2023) - "In summary, TST003 is a first-in-class therapeutic mAb targeting Gremlin-1 overexpressed by CAFs and tumor cells. Our preclinical characterization results provided the rationale for on-going clinical evaluation of TST003 in patients with advanced solid tumors with high unmet medical need either as monotherapy or in combination with SoC."

IO biomarker • Preclinical • Tumor cell • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • CAFs • KRAS • PD-L1 • TGFB1

Transcenta to Present Two Preclinical Studies at AACR 2023 (PRNewswire) - "Transcenta Holding Limited...announces that two preclinical studies in relation to TST003, a First-in-Class mAb Targeting GREMLIN-1, and TST010, an ADCC enhanced anti-CD25 mAb will be presented as posters at the American Association for Cancer Research (AACR) Annual Meeting 2023."

Preclinical • Oncology

Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors (PRNewswire) - "Transcenta Holding Limited...announces the successful dosing of first patient in the U.S. Phase I Study of TST003 (NCT05731271), its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, for the treatment of solid tumors. NCT05731271 is an open-label, dose escalation, FIH study designed to evaluate the safety, tolerability, and pharmacokinetics profile of TST003 as a treatment in patients with solid tumors."

Trial status • Oncology • Solid Tumor

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov) - P1/2 | N=76 | Recruiting | Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov) - P1/2 | N=76 | Not yet recruiting | Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Metastases • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor

Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors (PRNewswire) - "Transcenta Holding Limited...announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). Transcenta presented the latest progress of TST003 program at the 10th TEMTIA meeting in October 2022. Preclinical data showed that TST003 blocks EMT and displays potent single agent anti-tumor activities in PDX models of multiple difficult-to-treat solid tumors."

New trial • Preclinical • Oncology • Solid Tumor

Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update (PRNewswire) - "Transcenta Holding Limited...announces that the management team will collaborate with major brokerage firms and asset management firms to organize three exchange sessions in November 2022."

Clinical data • Pipeline update • Oncology • Solid Tumor

"#Transcenta To Present First-In-Class #TST003 #Antibody Program at the 10th #TEMTIAMeeting https://t.co/2Y6viY7kNF" (@1stOncology)

Transcenta To Present First-In-Class TST003 Antibody Program at the 10th TEMTIA Meeting (PRNewswire) - "Transcenta Holding Limited...announces that Transcenta is invited to participate the 10th TEMTIA meeting in Paris, France, November 7 to 10 and present preclinical data of TST003, Transcenta's first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1."

Preclinical • Oncology • Solid Tumor

Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors (PRNewswire) - "Transcenta Holding Limited...announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from U.S. Food and Drug Administration (FDA)....'We look forward to initiating our first time in human clinical study which is designed to address key questions to optimize TST003 clinical development plan'."

IND • Oncology • Solid Tumor